Fate Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fate Therapeutics, Inc. on June 15, 2026, regarding events occurring on June 12, 2026. The report details the outcomes of the Company's Annual Meeting of Stockholders held on that date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan amendments rather than financial performance results.
Material Changes and Corporate Actions
- Stock Plan Amendment: Stockholders approved a third amendment to the 2022 Stock Option and Incentive Plan, increasing the maximum number of shares available for issuance by 7,000,000 shares.
- Director Elections: Three Class I Directors were elected to serve until the 2029 Annual Meeting: Robert S. Epstein, M.D., M.S.; Karin Jooss, Ph.D.; and Laura J. Hamill.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive Compensation: A non-binding advisory vote to approve named executive officer compensation was passed.
Voting Results and Participation
Of the 116,281,693 shares entitled to vote, 87,134,422 shares were present or represented by proxy. All proposals were approved. Notable voting statistics include:
- Stock Plan Increase: 46,645,607 votes For; 14,304,810 votes Against; 100,245 Abstentions.
- Executive Compensation: 59,168,689 votes For; 1,808,669 votes Against; 73,304 Abstentions.
- Broker Non-Votes: 26,083,760 broker non-votes were recorded for the director elections and executive compensation vote.
Outlook, Risks, and Contingencies
The filing text does not provide specific guidance, outlook, management commentary on future operations, or new risk factors. The document serves strictly to report the results of the shareholder vote and the amendment to the equity incentive plan.
Key Facts for Investor Verification
- Verify the impact of the 7,000,000 share increase on potential future dilution.
- Review the Definitive Proxy Statement (filed April 24, 2026) for details on the specific compensation packages approved in the advisory vote.
- Confirm the tenure and background of the newly elected Class I Directors.
- Note that the significant number of broker non-votes (26,083,760) indicates a large portion of shares held in street name did not receive voting instructions for the director and compensation proposals.